Thought you might appreciate this item(s) I saw at Clinical Nuclear Medicine.
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues has been proven to be very useful in the management of advanced, well-differentiated neuroendocrine neoplasms (NENs). We present here the pregnancy outcome in a NEN patient, who naturally conceived and gave birth to a healthy baby, after 4 cycles of PRRT administering a cumulative radioactivity of 27.1 GBq. This case underlines that pregnancy and birth without sequelae are possible in patients with NEN who have been treated with PRRT and offers a definitive prospect for patients of reproductive age group who plan conception despite having received or due to undergo PRRT.
From the THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
Received for publication June 20, 2018; revision accepted July 20, 2018.
Correspondence to: Richard P. Baum MD, PhD, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany. E-mail: richard.baum@zentralklinik.de.
Clinical Nuclear Medicine43(11):842-845, November 2018.
Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?